With the current continuous expansion of the biopharmaceuticals market, investments in biotech R&D has yielded better returns than the pharma-industry average. The number of biotech patents applied for every year has been growing at 25 percent annually since 1995, and the success rate for biologics has so far been over twice that of small-molecule products.
To meet the changing demands of the modern world, MiGenTra Egypt has established state of the art R&D labs which are continuously upgraded with latest technologies
to support the development of our pipeline products, where the last few years have seen a significant expansion in its footprint, facilities and capabilities.